Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Feb 2.

Published in final edited form as: J Am Coll Cardiol. 2010 Feb 2;55(5):441–450. doi: 10.1016/j.jacc.2009.07.069

Incident rates for (A) new onset heart failure (HF) and (B) cardiovascular (CV) death based on change or absence of change between baseline and follow-up amino terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Change in NT-proBNP level is defined among those with a baseline NT-proBNP <190 pg/mL as either a decrease in NT-proBNP of at least 25% or an increase of at least 25% to a level ≥ 190 pg/mL. Change in NT-proBNP level is defined among those with a baseline NT-proBNP ≥190 pg/mL as either a decline of at least 25% to a level <190 pg/mL or an increase of >25%.

Incident rates for (A) new onset heart failure (HF) and (B) cardiovascular (CV) death based on change or absence of change between baseline and follow-up amino terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Change in NT-proBNP level is defined among those with a baseline NT-proBNP <190 pg/mL as either a decrease in NT-proBNP of at least 25% or an increase of at least 25% to a level ≥ 190 pg/mL. Change in NT-proBNP level is defined among those with a baseline NT-proBNP ≥190 pg/mL as either a decline of at least 25% to a level <190 pg/mL or an increase of >25%.